Premium
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-04-28 | Ms. Mary K. MorelandExec. VP of HR | 5,31k | 501,69k | Acquisition Under Employee Benefit Plan | 94,41 | 121,45k | 4,58% |
| 2026-04-27 | Mr. Daniel J. StarksIndependent Director | 10,00k | 926,54k | Achat | 92,65 | 6,73M | 0,15% |
| 2026-04-23 | Mr. Philip P. BoudreauCFO & Exec. VP of Finance | 2,20k | 201,30k | Achat | 91,50 | 82,65k | 2,73% |
| 2026-04-23 | Mr. Philip P. BoudreauCFO & Exec. VP of Finance | 8,91k | 819,98k | Acquisition Under Employee Benefit Plan | 92,04 | 82,65k | 12,08% |
| 2026-03-02 | Mr. Eric ShroffSVP of Rapid & Molecular Diagnostics | -709,00 | 81,95k | Vente | 115,58 | 39,16k | -1,78% |
| 2026-02-27 | Mr. Eric ShroffSVP of Rapid & Molecular Diagnostics | -1,38k | 160,90k | Sale to Issuer | 116,26 | 39,16k | -3,41% |
| 2026-02-27 | Mr. Christopher J. ScogginsExec. VP of Diabetes Care | -5,00k | 580,95k | Sale to Issuer | 116,26 | 77,13k | -6,08% |
| 2026-03-02 | Mr. Daniel Gesua Sive SalvadoriExec. VP and Group President of Established Pharmaceuticals & Nutritional Products | -885,00 | 102,29k | Vente | 115,58 | 146,38k | -0,60% |
| 2026-02-27 | Mr. Daniel Gesua Sive SalvadoriExec. VP and Group President of Established Pharmaceuticals & Nutritional Products | -6,62k | 769,06k | Sale to Issuer | 116,26 | 146,38k | -4,32% |
| 2026-03-02 | Mr. Louis H. MorroneExec. VP of Core Diagnostics | -1,14k | 132,22k | Vente | 115,58 | 76,86k | -1,47% |
| 2026-02-27 | Mr. Louis H. MorroneExec. VP of Core Diagnostics | -4,04k | 469,69k | Sale to Issuer | 116,26 | 76,86k | -4,99% |
| 2026-03-02 | Ms. Mary K. MorelandExec. VP of HR | -613,00 | 70,85k | Vente | 115,58 | 116,14k | -0,53% |
| 2026-02-27 | Ms. Mary K. MorelandExec. VP of HR | -4,63k | 538,28k | Sale to Issuer | 116,26 | 116,14k | -3,83% |
| 2026-03-02 | Mr. John A. McCoyVP of Finance & Controller | -585,00 | 67,61k | Vente | 115,58 | 24,69k | -2,31% |
| 2026-02-27 | Mr. John A. McCoyVP of Finance & Controller | -1,14k | 132,77k | Sale to Issuer | 116,26 | 24,69k | -4,42% |
| 2026-02-27 | Mr. Robert B. FordChairman, President & CEO | -30,31k | 3,52M | Sale to Issuer | 116,26 | 522,66k | -5,48% |
| 2026-02-27 | Ms. Lisa D. EarnhardtExec. VP & Group President of Medical Devices | -8,58k | 997,16k | Sale to Issuer | 116,26 | 90,41k | -8,67% |
| 2026-03-02 | Ms. Elizabeth CushmanExec. VP, General Counsel & Secretary | -263,00 | 30,40k | Vente | 115,58 | 38,57k | -0,68% |
| 2026-02-27 | Ms. Elizabeth CushmanExec. VP, General Counsel & Secretary | -1,42k | 165,21k | Sale to Issuer | 116,26 | 38,57k | -3,55% |
| 2026-02-27 | Mr. Philip P. BoudreauCFO & Exec. VP of Finance | -7,44k | 865,09k | Sale to Issuer | 116,26 | 71,54k | -9,42% |
| 2026-02-04 | Mr. Daniel J. StarksIndependent Director | 10,00k | 1,09M | Achat | 108,33 - 109,14 | 6,72M | 0,15% |
| 2026-01-23 | Mr. Robert B. FordChairman, President & CEO | 18,80k | 2,01M | Achat | 107,13 | 469,51k | 4,17% |
| 2025-12-11 | Mr. Daniel Gesua Sive SalvadoriExec. VP and Group President of Established Pharmaceuticals & Nutritional Products | -1,54k | 189,36k | Other Disposition | 123,28 | 132,23k | -1,15% |
| 2025-11-25 | Mr. Eric ShroffSVP of Rapid & Molecular Diagnostics | -1,59k | 203,04k | Vente | 128,02 | 30,38k | -4,96% |
| 2025-09-01 | Mr. John A. McCoyVP of Finance & Controller | -79,00 | 10,48k | Sale to Issuer | 132,66 | 21,04k | -0,37% |
| 2025-09-01 | Mr. Philip P. BoudreauCFO & Exec. VP of Finance | -387,00 | 51,34k | Sale to Issuer | 132,66 | 50,98k | -0,75% |
| 2025-08-08 | Mr. Philip P. BoudreauCFO & Exec. VP of Finance | -5,55k | 746,76k | Vente | 134,55 | 51,36k | -9,75% |
| 2025-06-30 | Mr. Louis H. MorroneExec. VP of Core Diagnostics | -269,00 | 36,15k | Sale to Issuer | 134,38 | 66,62k | -0,40% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
